Efter to år var 93, 5% (p=0, 004) og 86, 4% af de patienter, som fik henholdsvis Bondenza 150 mg én gang om måneden eller ibandronsyre 2, 5 mg daglig, respondenter.
At two years, 93.5% (p=0.004) and 86.4% of patients receiving Bondenza 150 mg once monthly or ibandronic acid 2.5 mg daily, respectively, were responders.